Io Therapeutics Phase II Clinical Stage and Preclinical Retinoid Compounds for Treatment of Cancers
Martin E. Sanders, M.D., Vidyasagar Vuligonda, Ph.D., March 2025
IRX4204: A Phase II Clinical Stage Third Generation RXR Nuclear Receptor Agonist for Treatment of Alzheimer’s Disease and Other Dementias
Martin E. Sanders, M.D., Vidyasagar Vuligonda, Ph.D., March 2025
IRX4204: An RXR Nuclear Receptor Agonist for Treatment of Neuroinflammatory Demyelinating Conditions Stroke, CNS Injury, MS, ALS, and Normal Aging-related Neurodegeneration
Martin E. Sanders, M.D., Vidyasagar Vuligonda, Ph.D., March 2025
IRX4204 – A Clinical Stage Potent and Selective RXR Agonist Compound for Treatment of Psoriasis and other Autoimmune Skin Diseases
Martin E. Sanders, M.D., Vidyasagar Vuligonda, Ph.D, March 2025
IRX4204 for Parkinson’s Disease
Martin E. Sanders, M.D., Vidyasagar Vuligonda, Ph.D, March 2025